184 related articles for article (PubMed ID: 31515668)
1. Downregulation of SRSF3 by antisense oligonucleotides sensitizes oral squamous cell carcinoma and breast cancer cells to paclitaxel treatment.
Sun Y; Yan L; Guo J; Shao J; Jia R
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1133-1143. PubMed ID: 31515668
[TBL] [Abstract][Full Text] [Related]
2. Inclusion of hnRNP L Alternative Exon 7 Is Associated with Good Prognosis and Inhibited by Oncogene SRSF3 in Head and Neck Squamous Cell Carcinoma.
Xu L; Shen J; Jia J; Jia R
Biomed Res Int; 2019; 2019():9612425. PubMed ID: 31828152
[TBL] [Abstract][Full Text] [Related]
3. SRSF5 functions as a novel oncogenic splicing factor and is upregulated by oncogene SRSF3 in oral squamous cell carcinoma.
Yang S; Jia R; Bian Z
Biochim Biophys Acta Mol Cell Res; 2018 Sep; 1865(9):1161-1172. PubMed ID: 29857020
[TBL] [Abstract][Full Text] [Related]
4. HnRNP L is important for the expression of oncogene SRSF3 and oncogenic potential of oral squamous cell carcinoma cells.
Jia R; Zhang S; Liu M; Zhang Y; Liu Y; Fan M; Guo J
Sci Rep; 2016 Nov; 6():35976. PubMed ID: 27808105
[TBL] [Abstract][Full Text] [Related]
5. Down-Regulation of Nucleolar and Spindle-Associated Protein 1 (NUSAP1) Expression Suppresses Tumor and Cell Proliferation and Enhances Anti-Tumor Effect of Paclitaxel in Oral Squamous Cell Carcinoma.
Okamoto A; Higo M; Shiiba M; Nakashima D; Koyama T; Miyamoto I; Kasama H; Kasamatsu A; Ogawara K; Yokoe H; Tanzawa H; Uzawa K
PLoS One; 2015; 10(11):e0142252. PubMed ID: 26554377
[TBL] [Abstract][Full Text] [Related]
6. Expression of SRSF3 is Correlated with Carcinogenesis and Progression of Oral Squamous Cell Carcinoma.
Peiqi L; Zhaozhong G; Yaotian Y; Jun J; Jihua G; Rong J
Int J Med Sci; 2016; 13(7):533-9. PubMed ID: 27429590
[TBL] [Abstract][Full Text] [Related]
7. Oncogene SRSF3 suppresses autophagy via inhibiting BECN1 expression.
Zhou L; Guo J; Jia R
Biochem Biophys Res Commun; 2019 Feb; 509(4):966-972. PubMed ID: 30654935
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel in combination with cetuximab exerts antitumor effect by suppressing NF-κB activity in human oral squamous cell carcinoma cell lines.
Harada K; Ferdous T; Kobayashi H; Ueyama Y
Int J Oncol; 2014 Dec; 45(6):2439-45. PubMed ID: 25230791
[TBL] [Abstract][Full Text] [Related]
9. PTBP1 and PTBP2 impaired autoregulation of SRSF3 in cancer cells.
Guo J; Jia J; Jia R
Sci Rep; 2015 Sep; 5():14548. PubMed ID: 26416554
[TBL] [Abstract][Full Text] [Related]
10. An anti-PD-1 antisense oligonucleotide promotes the expression of soluble PD-1 by blocking the interaction between SRSF3 and an exonic splicing enhancer of PD-1 exon 3.
Wang X; Yan L; Guo J; Jia R
Int Immunopharmacol; 2024 Jan; 126():111280. PubMed ID: 38043270
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel Potentiates the Anticancer Effect of Cetuximab by Enhancing Antibody-Dependent Cellular Cytotoxicity on Oral Squamous Cell Carcinoma Cells In Vitro.
Sawatani Y; Komiyama Y; Nakashiro KI; Uchida D; Fukumoto C; Shimura M; Hasegawa T; Kamimura R; Hitomi-Koide M; Hyodo T; Kawamata H
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878053
[TBL] [Abstract][Full Text] [Related]
12. miR-21 inhibitor sensitizes human OSCC cells to cisplatin.
Wang W; Songlin P; Sun Y; Zhang B; Jinhui W
Mol Biol Rep; 2012 May; 39(5):5481-5. PubMed ID: 22249446
[TBL] [Abstract][Full Text] [Related]
13. SRSF3-Regulated RNA Alternative Splicing Promotes Glioblastoma Tumorigenicity by Affecting Multiple Cellular Processes.
Song X; Wan X; Huang T; Zeng C; Sastry N; Wu B; James CD; Horbinski C; Nakano I; Zhang W; Hu B; Cheng SY
Cancer Res; 2019 Oct; 79(20):5288-5301. PubMed ID: 31462429
[TBL] [Abstract][Full Text] [Related]
14. Serine/Arginine-Rich Splicing Factor 3 Modulates the Alternative Splicing of Cytoplasmic Polyadenylation Element Binding Protein 2.
DeLigio JT; Stevens SC; Nazario-Muñoz GS; MacKnight HP; Doe KK; Chalfant CE; Park MA
Mol Cancer Res; 2019 Sep; 17(9):1920-1930. PubMed ID: 31138601
[TBL] [Abstract][Full Text] [Related]
15. Serine/arginine-rich splicing factor 3 (SRSF3) regulates homologous recombination-mediated DNA repair.
He X; Zhang P
Mol Cancer; 2015 Aug; 14():158. PubMed ID: 26282282
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.
Zheng P; Dong L; Zhang B; Dai J; Zhang Y; Wang Y; Qin S
Histochem Cell Biol; 2019 Oct; 152(4):281-291. PubMed ID: 31352515
[TBL] [Abstract][Full Text] [Related]
17. Pathways Related to the Anti-Cancer Effects of Metabolites Derived from Cerrado Biome Native Plants: An Update and Bioinformatics Analysis on Oral Squamous Cell Carcinoma.
Xavier GM; Guimarães ALS; de Carvalho Fraga CA; Guimarães TA; de Souza MG; Jones KM; Farias LC
Protein Pept Lett; 2021; 28(7):735-749. PubMed ID: 33302827
[TBL] [Abstract][Full Text] [Related]
18. Glutathione-sensitive and folate-targeted nanoparticles loaded with paclitaxel to enhance oral squamous cell carcinoma therapy.
Fan L; Wang J; Xia C; Zhang Q; Pu Y; Chen L; Chen J; Wang Y
J Mater Chem B; 2020 Apr; 8(15):3113-3122. PubMed ID: 32207763
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1.
Dong XL; Xu PF; Miao C; Fu ZY; Li QP; Tang PY; Wang T
Biomed Pharmacother; 2012 Feb; 66(1):70-5. PubMed ID: 22264882
[TBL] [Abstract][Full Text] [Related]
20. SRSF3 and hnRNP H1 regulate a splicing hotspot of HER2 in breast cancer cells.
Gautrey H; Jackson C; Dittrich AL; Browell D; Lennard T; Tyson-Capper A
RNA Biol; 2015; 12(10):1139-51. PubMed ID: 26367347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
